aurobindo pharma (citi) Growth on Track

Growth despite setbacks; 4Q revenues strong, margins lower than expected; Revenues strong across segments; Ending FY11 on a sound note
Date Rating Target Price Recommendation Price Broker house
9 May 2011 buy 285 181 citi Report

No comments:

Post a Comment